On March 31, 2020, SanBio, Co. announced that it had entered into a development and commercialization alliance with Ocumension (Hong Kong) Limited. Wilson Sonsini Goodrich & Rosati advised SanBio in the agreement.
SanBio and Ocumension entered into their collaboration to accelerate the research, development, and commercialization of innovative stem cell therapies for ophthalmic diseases. According to the announcement, both companies will jointly develop SanBio’s proprietary modified mesenchymal stem cell medicines with an initial focus in retinitis pigmentosa and dry age-related macular degeneration and optic neuritis.
The Wilson Sonsini team advising SanBio was led by Ian Edvalson. Please see the press release for more information.